KIF11 has become a target for anti-cancer drug development. Inhibitors of KIF11, such as ispinesib and monastrol, have shown promising results in preclinical studies by inducing cell cycle arrest and apoptosis in cancer cells. These inhibitors prevent the proper formation of the mitotic spindle, thereby halting cell division and leading to cell death.
